Understanding the pathogenesis of allergic asthma using mouse models

被引:62
作者
Leong, KP
Huston, DP
机构
[1] Tan Tock Seng Hosp, Dept Rheumatol & Immunol, Singapore 308433, Singapore
[2] Baylor Coll Med, Dept Med, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA
关键词
D O I
10.1016/S1081-1206(10)62201-6
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Objective: This paper reviews the current views of the pathogenesis of airway eosinophilic inflammation and airway hyperresponsiveness (AHR) in allergic asthma based on mouse models of the disease. The reader will also encounter new treatment strategies that have arisen as this knowledge is applied in practice. Data sources: MEDLINE searches were conducted with key words asthma, mouse model, and murine. Additional articles were identified from references in articles and book chapters. Study selection: Original research papers and review articles from peer-reviewed journals were chosen. Results: Although the mouse model does not replicate human asthma exactly, the lessons learned about the pathogenesis of allergic airway inflammation and AHR are generally applicable in humans. Type 2 T helper lymphocytes (Th2) orchestrate the inflammation and are crucial for the development of AHR. Cells and molecules involved in T cell activation (dendritic cells, T cell receptor, major histocompatibility complex molecule. and costimulatory molecules) are also vital. Besides these, no other cell or molecule could be shown to be indispensable for the establishment of the model under all experimental conditions. There are at least three pathways that lead to AHR. One is dependent on immunoglobulin E and mast cells. one on eosinophils and interleukin-5 (IL-5), and one on IL-13. Eosinophils are probably the most important effector cells of AHR. Radical methods to treat asthma have been tested in the animal model. including modifying the polarity of lymphocyte response and antagonizing IL-5. Conclusions: AHR. the hallmark of asthma, is attributable to airway inflammation ultimately mediated by helper T cells via three pathways, at least. The mouse model is also a valuable testing ground for new therapies of asthma.
引用
收藏
页码:96 / 109
页数:14
相关论文
共 179 条
[21]   Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity [J].
Corry, DB ;
Folkesson, HG ;
Warnock, ML ;
Erle, DJ ;
Matthay, MA ;
WienerKronish, JP ;
Locksley, RM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (01) :109-117
[22]   Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma [J].
Crimi, E ;
Spanevello, A ;
Neri, M ;
Ind, PW ;
Rossi, GA ;
Brusasco, V .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (01) :4-9
[23]   EARLY IDENTIFICATION OF INTERLEUKIN-16 (LYMPHOCYTE CHEMOATTRACTANT FACTOR) AND MACROPHAGE INFLAMMATORY PROTEIN 1-ALPHA (MIP1-ALPHA) IN BRONCHOALVEOLAR LAVAGE FLUID OF ANTIGEN-CHALLENGED ASTHMATICS [J].
CRUIKSHANK, WW ;
LONG, A ;
TARPY, RE ;
KORNFELD, H ;
CARROLL, MP ;
TERAN, L ;
HOLGATE, ST ;
CENTER, DM .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1995, 13 (06) :738-747
[24]  
Dasic G, 1999, EUR J IMMUNOL, V29, P2957, DOI 10.1002/(SICI)1521-4141(199909)29:09<2957::AID-IMMU2957>3.0.CO
[25]  
2-4
[26]   Effect of interleukin-16-blocking peptide on parameters of allergic asthma in a murine model [J].
de Bie, JJ ;
Henricks, PAJ ;
Cruikshank, WW ;
Hofman, G ;
Nijkamp, FP ;
van Oosterhout, AJM .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 383 (02) :189-196
[27]   Interleukin-8 receptor modulates IgE production and B-cell expansion and trafficking in allergen-induced pulmonary inflammation [J].
de Sanctis, GT ;
MacLean, JA ;
Qin, SX ;
Wolyniec, WW ;
Grasemann, H ;
Yandava, CN ;
Jiao, AP ;
Noonan, T ;
Stein-Streilein, J ;
Green, FHY ;
Drazen, JM .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (04) :507-515
[28]   Contribution of nitric oxide synthases 1, 2, and 3 to airway hyperresponsiveness and inflammation in a murine model of asthma [J].
De Sanctis, GT ;
MacLean, JA ;
Hamada, K ;
Mehta, S ;
Scott, JA ;
Jiao, AP ;
Yandava, CN ;
Kobzik, L ;
Wolyniec, WW ;
Fabian, AJ ;
Venugopal, CS ;
Grasemann, H ;
Huang, PL ;
Drazen, JM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (10) :1621-1629
[29]  
DeBie JJ, 1996, BRIT J PHARMACOL, V119, P1484
[30]   Nebulized lidocaine in the treatment of severe asthma in children: a pilot study [J].
Decco, ML ;
Neeno, TA ;
Hunt, LW ;
O'Connell, EJ ;
Yunginger, JW ;
Sachs, MI .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1999, 82 (01) :29-32